Eli Lilly Raises Outlook as Mounjaro and Zepbound Sales Exceed Expectations

Eli Lilly Raises Outlook as Mounjaro and Zepbound Sales Exceed Expectations
1 min readBusinessHealthMarkets

In Brief

Strong demand for Eli Lilly's GLP-1 drugs has prompted the company to increase its full-year sales and profit guidance.

Key Facts

  • Eli Lilly increased its full-year sales outlook by $2 billion.
  • The company also raised its adjusted profit guidance.
  • Sales of Mounjaro and Zepbound both surpassed analyst expectations.
  • Lilly's stock price rallied following the sales report.
  • Sales of GLP-1 drugs nearly doubled, according to MarketWatch.

What Happened

Eli Lilly reported higher-than-expected sales for its GLP-1 drugs Mounjaro and Zepbound, leading the company to raise its full-year sales and profit outlook.

Why It Matters

The strong performance of these drugs underscores their growing role in Eli Lilly's business and reflects broader demand for GLP-1 treatments in the pharmaceutical market.

What's Next

Investors and analysts will monitor whether demand for Mounjaro and Zepbound continues to drive growth and if Eli Lilly maintains its revised outlook in future quarters.

Sources